Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

3 results about "Factor VII" patented technology

Factor VII (EC 3.4.21.21, blood-coagulation factor VIIa, activated blood coagulation factor VII, formerly known as proconvertin) is one of the proteins that causes blood to clot in the coagulation cascade. It is an enzyme of the serine protease class. A recombinant form of human factor VIIa (eptacog alfa [activated], NovoSeven) has U.S. Food and Drug Administration approval for uncontrolled bleeding in hemophilia patients. It is sometimes used unlicensed in severe uncontrollable bleeding, although there have been safety concerns. A biosimilar form of recombinant activated factor VII (AryoSeven) is also available, but does not play any considerable role in the market.

Methods of treating hemophilic arthropathy using chimeric coagulation factors

To provide a method for treating reversible hemophilic arthropathy of a joint in a human having hemophilia.SOLUTION: Uses of a chimeric protein or composition comprising a coagulation factor and an Fc region are provided. The coagulation factor is selected from the group consisting of Factor VII (FVII), Factor VIIa (FVIIa), Factor VIII (FVIII), Factor IX (FIX), Factor X (FX), von Willebrand Factor (VWF), an antigen-binding portion thereof that specifically binds to FIX and FX, or any combination thereof.SELECTED DRAWING: None
Owner:BIOVERATIV THERAPEUTICS INC

Method and kit for monitoring anticoagulant therapy

ActiveUS12681025B2Test sampleFactor ii
A method and kit are provided for measuring and monitoring a combined effect of an anticoagulant drug on coagulation factors II and X in a patient taking the anticoagulant drug. The method includes adding one or more coagulation reagents with the factor VII to a test sample and determining blood clotability of the test sample by measuring an influence of factors II and X.
Owner:FIIX DIAGNOSTICS

Combination of factor vii and a Anti-factor ix and factor x bispecific antibody

ActiveRS64646B2Antiendomysial antibodiesFactor X
A pharmaceutical composition comprising: a. transgenic Factor VII and b. a multispecific antibody directed against Factor IX and Factor X. The patent application contains 10 more claims.
Owner:LABE FR DU FRACTIONNEMENT & DES BIOTECH SA